

High Cost Claimants among Active Employees and Early Retirees and Their Dependents

March 2019



Overview

Objectives:

- Examine high level cost and utilization for High Cost Claimants (HCCs).
- Provide a snapshot of what portion of the HCC population continues to incur high costs over time.
- Provide a demographic overview of HCCs.
- Understand the top clinical conditions experienced by high cost claimants.
- Identify the highest cost cases and provide a profile to understand variation in contributing conditions.




Analytic Parameters

- Active Employees & Early Retirees, Their Spouses and Dependents
- Age Limited to 64 and Younger & Medicaid excluded
- Rolling year periods (November – October)
- HCCs are patients with \$100,000 or more of incurred claims during the reporting period.

High Cost Claimants (HCCs) Trends

Over the most recent 48 month period available for analysis:

- the proportion of HCCs with respect to the overall membership in the observed cohort, increased from 5.7 patients per 1,000 to 7.2 patients per 1,000 over the most recent 4 rolling year periods;
- the percent of net payments attributable to HCCs increased from about one fifth of payments to just over one quarter of payments;
- net payments per member per month (PMPM) increased for High Cost Claimants from \$97 to \$132; and
- the net payment PMPM trend for HCCs far exceeded the trend for non-HCCs in each of the observed periods.



Patient Stratification by Net Payment Range

November 2017 – October 2018

Range	Patients	Total Net Payments	Net Medical Payments	Net Rx Payments	Cumulative Percent of Patients	Cumulative Percent of Total Net Payments
\$0.00	1335	0	0	0	100.0%	100.0%
\$0.01 - \$4,999.99	74225	\$93,342,072	\$71,281,424	\$22,033,029	98.6%	100.0%
\$5,000.00 - \$9,999.99	8878	\$61,840,414	\$45,351,788	\$16,485,998	21.6%	84.3%
\$10,000.00 - \$14,999.99	3713	\$45,004,889	\$33,826,424	\$11,177,060	12.4%	73.8%
\$15,000.00 - \$19,999.99	2183	\$37,350,855	\$29,221,297	\$8,128,846	8.5%	66.2%
\$20,000.00 - \$29,999.99	2178	\$52,281,141	\$40,917,782	\$11,362,658	6.3%	60.0%
\$30,000.00 - \$39,999.99	1134	\$38,796,495	\$30,240,544	\$8,555,452	4.0%	51.1%
\$40,000.00 - \$49,999.99	684	\$30,206,567	\$23,262,831	\$6,943,537	2.8%	44.6%
\$50,000.00 - \$99,999.99	1281	\$87,342,848	\$62,141,695	\$25,200,490	2.1%	39.5%
over \$99,999.99	750	\$146,966,787	\$126,107,380	\$20,859,250	0.8%	24.8%
Totals	96361	\$593,124,745	\$462,343,842	\$130,746,320	100.0%	100.0%

- About 20% of the patient population accounted for about 85% of total net payments.
- Less than 1% of the population were High Cost Claimants (HCCs). HCCs accounted for just under 25% of total net payments.

High Cost Claimants – Patients and Net Payments by Service Category

November 2017 – October 2018

Service Category	Patients	Net Payments
Facility Inpatient	437	\$53.8 M
Facility Outpatient	676	\$42.4 M
Laboratory Outpatient	698	\$1.3 M
Mental Health / Substance Abuse	218	\$2.4 M
Professional Services	731	\$10.8 M
Physician Inpatient	463	\$5.0 M
Physician Outpatient	746	\$2.7 M
Prescription Drugs	735	\$20.8 M
Radiology Outpatient	322	\$8.2 M

High Cost Claimants & Top 50 Highest Cost Claimants (HCCs) Net Payment Range for Current Rolling Year (CRY) and Three Year Experience

	All High Cost Claimants	Top 50 Highest Cost Claimants
Patients in CRY	750	50
Range of Net Payments in CRY	\$100,068 - \$2,134,705	\$414,226 - \$2,134,705
HCCs in CRY only	504 (67.2%)	25 (50%)
HCCs in CRY & Previous Rolling Year (PRY)	142 (18.9%)	11 (22%)
HCCs in CRY & 2 PRYs	89 (11.9%)	13 (26%)
HCCs in CRY and Nov 15–Oct 16 RY	15 (2.0%)	1 (2.0%)

- Of the 750 High Cost Claimants in the CRY, 43 (5.7%) were no longer enrolled in one of the four plans for active employees and early retirees at the end of the reporting period.

Current Rolling Year High Cost Claimants & Top 50 Highest Cost Claimants (HCCs) by Plan, Gender and Age Group¹

Highmark Plans	Gender	Age Group	Top 50 HCCs (% of Cohort)	All HCCs (% of Cohort)
First State Basic	Female	Infant	---	1 (0.1%)
		1 to 17	---	---
		18-40	---	2 (0.3%)
		41-64	1 (2%)	7 (0.9%)
	Male	Infant	---	1 (0.1%)
		1 to 17	---	1 (0.1%)
		18-40	---	2 (0.3%)
		41-64	1 (2%)	13 (1.7%)
PPO	Female	Infant	1 (2%)	12 (1.6%)
		1 to 17	3 (6%)	23 (3.1%)
		18-40	2 (4%)	45 (6.0%)
		41-64	13 (26%)	225 (30.0%)
	Male	Infant	3 (6%)	10 (1.3%)
		1 to 17	3 (6%)	25 (3.3%)
		18-40	1 (2%)	27 (3.6%)
		41-64	8 (16%)	184 (24.4%)

Current Rolling Year High Cost Claimants & Top 50 Highest Cost Claimants (HCCs) by Plan, Gender and Age Group

Aetna Plans	Gender	Age Group	Top 50 HCCs (% of Cohort)	All HCCs(% of Cohort)
CDPH Gold	Female	Infant	---	1 (0.1%)
		1 to 17	---	1 (0.1%)
		18-40	---	4 (0.5%)
		41-64	1 (2%)	9 (1.2%)
	Male	Infant	---	1 (0.1%)
		1 to 17	---	---
		18-40	---	2 (0.3%)
		41-64	1 (2%)	12 (1.6%)
HMO	Female	Infant	---	---
		1 to 17	1 (2%)	6 (0.8%)
		18-40	4 (8%)	14 (1.9%)
		41-64	1 (2%)	86 (11.5%)
	Male	Infant	---	3 (0.4%)
		1 to 17	2 (4%)	4 (0.5%)
		18-40	---	5 (0.7%)
		41-64	6 (12%)	65 (8.7%)

Top Clinical Conditions by Total Net Payments for the Top 50 Highest Cost Claimants (HCCs) November 2017 – October 2018

	Net Payments	Patients	Net Pay per Patients
Chemotherapy Encounters	\$4,777,311	15	\$318,487
Musculosk Disord, Congenital	\$2,236,436	3	\$745,479
Hypertension, Essential	\$2,093,675	24	\$87,236
Respiratory Disord, NEC	\$1,637,194	31	\$52,813
Newborns, w/wo Complication	\$1,629,479	4	\$407,370
Gastroint Disord, NEC	\$1,397,109	29	\$48,176
Hematologic Disord, NEC	\$1,361,719	21	\$64,844
Renal Function Failure	\$1,235,905	16	\$77,244
Condition Rel to Tx - Med/Surg	\$1,100,512	22	\$50,023
Cerebrovascular Disease	\$1,016,469	9	\$112,941

Top Clinical Conditions by Net Payment per Patient for Top 50 Highest Cost Claimants (HCCs) November 2017 – October 2018

	Net Payments	Patients	Net Pay per Patients
Musculosk Disord, Congenital	\$2,236,436	3	\$745,479
Newborns, w/wo Complication	\$1,629,479	4	\$407,370
Chemotherapy Encounters	\$4,777,311	15	\$318,487
Respiratory Disord, Congenital	\$307,279	1	\$307,279
Cancer - Prostate	\$195,285	1	\$195,285
Cancer - Lung	\$953,165	5	\$190,633
Alpha 1-Antitrypsin Deficiency	\$187,338	1	\$187,338
Cancer - Hepatobil Ex Pancreas	\$313,543	2	\$156,771
Cancer - Lymphoma	\$775,600	5	\$155,120
Foreign Body - Gastroint	\$298,771	2	\$149,386

Top Clinical Conditions by Patient Volume for the Top 50 Highest Cost Claimants (HCCs) November 2017 – October 2018

	Net Payments	Patients	Net Pay per Patients
Respiratory Disord, NEC	\$1,637,194	31	\$52,813
Gastroint Disord, NEC	\$1,397,109	29	\$48,176
Cardiovasc Disord, NEC	\$115,677	27	\$4,284
Hypertension, Essential	\$2,093,675	24	\$87,236
Neurological Disorders, NEC	\$870,337	23	\$37,841
Arthropathies/Joint Disord NEC	\$26,356	23	\$1,146
Condition Rel to Tx - Med/Surg	\$1,100,512	22	\$50,023
Hematologic Disord, NEC	\$1,361,719	21	\$64,844
Nutritional Disorders, NEC	\$125,957	20	\$6,298
Anemia, Ex Nutritional	\$818,698	18	\$45,483

Top 10 Highest Cost Claimants - Summary

November 2017 – October 2018

- The ten highest cost patients incurred \$11.4 million in total plan payments during the current rolling year.
- 95% of these costs were payments incurred on the medical benefit.
- About 5%, or \$583,600, were incurred on the prescription benefit.
- The ten highest cost patients had:
 - 33 hospital admissions;
 - 1,350 days in the hospital;
 - 18 emergency room visits; and
 - 1,712 patient visits (unique date and provider).

Top 10 Highest Cost Claimants Profile

November 2017 – October 2018

Status Relationship	Gender Age	Plan	Net Payments Net Medical Net Rx	Admits Days	Visits ER Visits	Episode Summary Group (Highest Cost) Top 3 Dx (Highest Cost)
Active Dependent	Male 15	PPO	\$2,134,705 \$2,127,879 \$6,826	3 149	2 172	Musculoskeletal Disorders, Congenital <ul style="list-style-type: none"> • Neuromuscular scoliosis, thoracolumbar region • Ventilator associated pneumonia • Spastic quadriplegic cerebral palsy
Active Dependent	Male Infant	PPO	\$1,608,525 \$1,608,525 ---	2 214	--- 220	Newborn Complications <ul style="list-style-type: none"> • Dyspnea, unspecified • Single liveborn infant, delivered by cesarean • Other disorders of lung
Active Employee	Male 62	PPO	\$1,447,104 \$1,446,347 \$757	2 106	4 140	Neurological Disorders <ul style="list-style-type: none"> • HTN heart & chr kidney disease w HF & stage 1 through 4 CKD or unspec • Other abnormalities of gait & mobility • Dilated cardiomyopathy

Top 10 Highest Cost Claimants Profile

November 2017 – October 2018

Status Relationship	Gender Age	Plan	Net Payments Net Medical Net Rx	Admits Days	Visits ER Visits	Episode Summary Group (Highest Cost) Top 3 Dx (Highest Cost)
Early Retiree Retiree	Female 64	PPO (from HMO)	\$1,305,443 \$1,304,310 \$1,133	2 232	--- 291	Gastrointestinal Disorders <ul style="list-style-type: none"> • Other postprocedural complications and disorders of digestive system • Chronic respiratory failure with hypoxia • Pyothorax with fistula
Active Spouse	Male 57	HMO	\$1,086,000 \$1,051,982 34,018	5 318	1 192	Cerebrovascular Disorders <ul style="list-style-type: none"> • Hemiplegia & hemiparesis follow nontraum SAH affect lt non-dominant side • Nontraumatic subarachnoid hemorrhage from other intracranial arteries • Other nontraumatic intracerebral hemorrhage
Active Spouse	Female 50	PPO	\$1,032,339 \$1,032,203 \$136	4 226	1 207	Skin Disorders <ul style="list-style-type: none"> • Infect & inflam reaction due to internal lt knee prosthesis, initial • Acute respiratory failure with hypoxia • Sepsis, unspecified organism



Top 10 Highest Cost Claimants Profile

November 2017 – October 2018

Status Relationship	Gender Age	Plan	Net Payments Net Medical Net Rx	Admits Days	Visits ER Visits	Episode Summary Group (Highest Cost) Top 3 Dx (Highest Cost)
Active Dependent	Male 18	PPO (From HMO)	\$746,597 \$310,733 \$435,864	3 26	2 123	Respiratory Disorder, Congenital <ul style="list-style-type: none"> • Cystic fibrosis with pulmonary manifestations • Cystic fibrosis, unspecified • Encounter for adjustment and management of vascular access device
Active Dependent	Female 3	PPO	\$687,687 \$684,130 \$3,557	6 41	4 135	Chemotherapy Encounters <ul style="list-style-type: none"> • Encounter for antineoplastic chemotherapy • Lymphoblastic (diffuse) lymphoma, intrathoracic lymph nodes • Encounter for antineoplastic chemotherapy
Early Retiree Retiree	Male 50	PPO	\$663,055 \$562,354 \$100,701	6 48	2 146	Signs/Symptoms/Oth Cond, NEC <ul style="list-style-type: none"> • Alcoholic cirrhosis of liver with ascites • Other ascites • Anemia, unspecified
Active Employee	Female 47	PPO	\$638,754 \$638,115 \$639	--- ---	2 87	Lipid Disorders <ul style="list-style-type: none"> • Fabry (-Anderson) disease • Carpal tunnel syndrome, right upper limb • Headache

